Nivo/Ipi Combo Now ' Standard of Care ' in Mesothelioma Nivo/Ipi Combo Now ' Standard of Care ' in Mesothelioma

Patients with malignant pleural mesothelioma have a marked and sustained overall survival benefit with nivolumab and ipilimumab vs chemotherapy, even if they discontinue treatment.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news